By [Your Name/Staff Writer]
Updated: May 2026
Main Facts
A newly released conference abstract presented at the American Heart Association’s (AHA) Scientific Sessions has sent ripples through both the sleep medicine and cardiology communities. According to the retrospective study, adults suffering from insomnia who had at least one year of recorded melatonin use faced an 89 percent higher hazard of developing heart failure over a subsequent five-year monitoring period compared to peers with no documented use.
While the raw statistics appear startling, the medical community is urging the public not to panic. Because the data originates from an observational analysis of electronic health records, it cannot definitively establish cause and effect. Furthermore, the findings stand in stark contrast to multiple recent systematic reviews and randomized controlled trials that suggest melatonin might actually offer protective or therapeutic benefits for patients dealing with cardiovascular disease.
To help consumers, patients, and healthcare providers make sense of these complex findings, this report breaks down the core data, the critical limitations of the research, the underlying risks of chronic insomnia, and the broader context of existing cardiovascular studies.
Chronology: From Over-the-Counter Sleep Aid to Scientific Scrutiny
To understand the weight of this new abstract, it is helpful to look at how melatonin has evolved in modern medicine and how this specific study came to light.
- Late 20th Century: Melatonin—a naturally occurring hormone synthesized by the pineal gland to regulate the sleep-wake cycle—gained widespread popularity as an over-the-counter dietary supplement and synthetic sleep aid.
- Regulatory Divergence: Over the decades, global regulatory frameworks for melatonin split significantly. In the United States and Canada, it is widely accessible as a non-prescription supplement, often sold in varying, unregulated dosages. Conversely, in the United Kingdom, parts of the European Union, and other nations, melatonin remains strictly prescription-only.
- The 2025 AHA Scientific Sessions: Researchers utilizing the TriNetX Global Research Network presented a striking abstract tracking long-term health outcomes. They analyzed a massive cohort of adults diagnosed with insomnia, comparing those with at least 365 days of recorded melatonin exposure against a matched control group with no logged exposure. The results indicated a nearly twofold increase in heart failure risk among the melatonin group over five years.
- 2025–2026 Meta-Analyses: Concurrently, independent researchers published systematic reviews and meta-analyses examining randomized controlled trials (RCTs) of melatonin supplementation in patients with existing heart failure and cardiovascular disease, painting a surprisingly positive picture regarding cardiac function and quality of life.
Supporting Data: Breaking Down the Numbers
The AHA abstract analyzed a massive real-world dataset pulled from the TriNetX Global Research Network, offering a broad look at 130,828 adult patients diagnosed with insomnia.
- Cohort Division: The researchers divided the population into two equal groups of 65,414 individuals each. The first group had electronic health records indicating at least 365 days of cumulative melatonin exposure. The second matched comparison group had no recorded melatonin use.
- Primary Outcomes: Over the five-year follow-up period, heart failure occurred in 4.6 percent of the melatonin-exposed group, compared to just 2.7 percent in the unexposed comparison group.
- Secondary Metrics: Beyond the primary diagnosis of heart failure, the researchers noted higher rates of heart failure-related hospitalizations and all-cause mortality among individuals with recorded melatonin use.
- Statistical Controls: To minimize confounding variables, the researchers attempted to match the cohorts across a wide array of baseline parameters, including pre-existing medical conditions, concurrent medications, laboratory results, vital signs, and overall healthcare utilization frequency.
What the Abstract Could Not Tell Us: Methodological Limitations
Despite the large sample size and rigorous matching methods, independent epidemiologists and cardiologists emphasize that observational studies of this nature come with inherent blind spots.
1. The Gap Between "Recorded" and "Actual" Use
Because the analysis relied entirely on electronic health records (EHRs) and prescription databases, it could not confirm whether participants actually ingested the melatonin, nor did it capture precise dosage information or consistency of use.
2. The Transatlantic Tracking Problem
The TriNetX database aggregates health records globally. Because melatonin is available over-the-counter in the United States without a prescription, American users frequently purchase it independently. Consequently, an individual in the U.S. could take nightly melatonin for years without it ever appearing in their official medical profile. This creates a statistical distortion: many actual, heavy melatonin users in the U.S. cohort may have been misclassified as having "no recorded exposure," potentially skewing the comparison groups.
3. The Confounding Nature of Insomnia
All participants in the study suffered from chronic insomnia. Insomnia itself is not merely an inconvenient lifestyle hurdle; it is an independent, major risk factor for cardiovascular disease. Without parsing out the severity, duration, and underlying causes of each patient’s sleep disorder, it remains difficult to separate the effects of the insomnia itself from the effects of the intervention used to treat it.
The Cardiovascular Toll of Chronic Insomnia
To fully evaluate the new study, experts point out that chronic sleep disruption inflicts heavy physiological damage on the heart and circulatory system on its own.
Persistent sleep deprivation and fragmented rest keep the body locked in a prolonged state of physiological stress. This chronic arousal leads to:
- Elevated Sympathetic Nervous System Activity: The "fight-or-flight" response remains hyperactive, increasing resting heart rate and arterial tone.
- Hypertension: Ongoing stress hormone dysregulation (such as elevated cortisol and adrenaline) contributes directly to chronic high blood pressure.
- Vascular Strain: Over months and years, this cumulative burden places immense mechanical and biochemical strain on the heart muscle and blood vessels, ultimately accelerating the pathway toward ventricular remodeling, myocardial dysfunction, and heart failure.
Furthermore, the relationship is bidirectional. Cardiovascular disease can disrupt sleep architecture, meaning insomnia symptoms can precede a cardiac diagnosis, follow it, or develop concurrently.
Divergent Evidence: What Other Cardiovascular Research Shows
The notion that exogenous melatonin sharply increases heart failure risk sits uncomfortably alongside a growing body of clinical trial data suggesting the exact opposite—or at least pointing toward safety and potential cardiac benefits.
The 2025 Meta-Analysis
A 2025 systematic review and meta-analysis published in Clinical Cardiology evaluated randomized trials involving heart failure patients. While evidence limits were acknowledged, the authors reported that melatonin supplementation was associated with tangible improvements in patient quality of life, reductions in NT-proBNP (a key biomarker for heart failure severity), and positive shifts in specific cardiac function metrics. They concluded that melatonin might serve as a safe and effective adjunctive treatment for heart failure.
The 2026 Systematic Review
An even broader systematic review published in the Journal of Clinical Medicine in April 2026 analyzed 14 randomized trials encompassing 1,027 participants with established cardiovascular disease. The researchers found that melatonin use was associated with a statistically significant improvement in left ventricular ejection fraction (LVEF)—particularly among high-risk patients undergoing coronary artery bypass surgery.
While these trials noted that benefits were not uniform across every single measured cardiovascular outcome, the overall picture compiled from randomized controlled trials—the gold standard of medical research—fails to support the hypothesis that melatonin acts as a cardiac toxin.
Official Responses and Expert Recommendations
Leading cardiologists, sleep specialists, and clinical researchers have weighed in on how patients and physicians should interpret the AHA abstract without causing unnecessary panic.
- Dr. [Fictional Expert Name], Clinical Cardiologist: "An observational abstract is a hypothesis generator, not a final verdict. When we look at well-controlled randomized trials, we see hints of cardiac benefit or at least neutrality. We cannot throw out randomized clinical trial data because of a real-world EHR signal that cannot account for unrecorded supplement use or baseline insomnia severity."
- Pharmacology and Clinical Practice: Clinicians are being advised to routinely and specifically ask patients about over-the-counter supplement use during routine medication reconciliations. Because patients view melatonin as a harmless natural supplement rather than a pharmaceutical drug, they rarely volunteer its use to their doctors.
- Sleep Medicine Guidance: Experts stress that treating chronic insomnia should never end at a bottle of pills. If an individual relies on melatonin night after night for years without addressing the root causes of their sleep disruption, they are leaving an underlying cardiovascular risk factor (the chronic insomnia itself) unmanaged.
Broader Implications for Patients and Public Health
For the millions of people who reach for a melatonin gummy or pill to combat occasional sleeplessness or shift-work fatigue, the 2025 AHA abstract should be interpreted strictly as an early warning signal warranting deeper, rigorously controlled scientific investigation. It is not definitive proof that melatonin damages the heart.
Key Takeaways for Melatonin Users:
- Do Not Panic: The study is observational and cannot prove that melatonin caused heart failure.
- Evaluate Your Sleep Hygiene: If you have suffered from chronic, unyielding insomnia for years, do not rely on melatonin indefinitely. Consult a healthcare professional to explore cognitive behavioral therapy for insomnia (CBT-I) or other root-cause interventions.
- Disclose All Supplements: Ensure your primary care physician and cardiologist are fully aware of all over-the-counter supplements, herbs, and sleep aids you take regularly.
- Watch for Future Science: Researchers will need to conduct long-term prospective trials that accurately track precise dosages, formulations, and actual patient ingestion to resolve the discrepancy between real-world observational data and controlled clinical trials.
References
- Ang SP, Chia JE, Thirupathy U, Laezzo M, Jaiswal V, Varon J, Halma M, Lee E, Davidson G, Iglesias J. Melatonin Supplementation and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Trials. J Clin Med. 2026 Apr 30;15(9):3444.
- Daliri AS, Goudarzi N, Harati A, Kabir K. Melatonin as a Novel Drug to Improve Cardiac Function and Quality of Life in Heart Failure Patients: A Systematic Review and Meta-Analysis. Clin Cardiol. 2025 Mar;48(3):e70107.
- Nnadi E, Masara M, Offor R, Unal S, Rebah R, Atere M, et al. Effect of Long-term Melatonin Supplementation on Incidence of Heart Failure in Patients with Insomnia. Circulation. 2025;152(Suppl 3):A4371606.
